Market Overview: Global Neutralizing Antibody Market Is Estimated To Witness High Growth Owing To the Growing Demand for COVID-19 Treatments
![]() |
Neutralizing Antibody Market |
The
global Neutralizing Antibody Market is estimated to be valued at US$1.62 billion in 2023 and is expected
to exhibit a CAGR of 7.5% over the
forecast period 2022-2030, as highlighted in a new report published by Coherent
Market Insights. Neutralizing antibodies are a type of antibody that can bind
to specific antigens and inhibit their biological activity. These antibodies
play a crucial role in combating viral infections, including the recent
COVID-19 pandemic. They are being extensively researched and utilized as a
potential treatment for COVID-19.
Market Key Trends: Rising Demand for Monoclonal Antibody Therapies
One key trend in the Neutralizing
Antibody Market is the increasing demand for monoclonal antibody
therapies. Monoclonal antibodies are produced in the laboratory and designed to
specifically target a particular antigen. They are being used as therapeutics
for various diseases, including cancer and autoimmune disorders. In the context
of COVID-19, monoclonal antibody therapies have shown promising results in
reducing disease severity and hospitalization rates.
For example, Regeneron Pharmaceuticals, Inc. developed a monoclonal antibody
cocktail (casirivimab and imdevimab) that received Emergency Use Authorization
(EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of
mild to moderate COVID-19 patients. These monoclonal antibodies have
demonstrated the ability to neutralize the SARS-CoV-2 virus and reduce viral
load, leading to improved clinical outcomes.
PEST Analysis:
Political: Governments worldwide are taking initiatives to support the
development and distribution of neutralizing antibodies for COVID-19 treatment.
Regulatory authorities are expediting the approval process to ensure timely
access to effective therapeutics.
Economic: The neutralizing antibody market is witnessing significant
investments from both public and private sectors. Pharmaceutical companies are
ramping up production capacity to meet the growing demand for antibody-based
therapies.
Social: The COVID-19 pandemic has created a global health crisis, raising
awareness about the importance of effective treatments. There is a growing
acceptance and demand for neutralizing antibodies as a potential strategy to
combat the virus.
Technological: Advancements in biotechnology and immunology have facilitated
the discovery and development of neutralizing antibodies. Innovative
manufacturing techniques, such as recombinant DNA technology, have improved
production efficiency and scalability.
Key Takeaways:
Paragraph 1: The global neutralizing antibody market is expected to witness
high growth, exhibiting a CAGR of 7.5% over the forecast period, due to
increasing demand for COVID-19 treatments. Neutralizing antibodies have shown
efficacy in reducing disease severity and improving clinical outcomes in
COVID-19 patients.
Paragraph 2: North America is expected to dominate the global neutralizing
antibody market due to favorable government initiatives, robust healthcare
infrastructure, and extensive research and development activities. Asia Pacific
is anticipated to be the fastest-growing region, driven by increasing
healthcare expenditure and rising awareness about advanced therapeutics.
Paragraph 3: Key players operating in the global neutralizing antibody market
include Regeneron Pharmaceuticals, Inc., Eli Lilly and Company, AstraZeneca
PLC, GlaxoSmithKline plc, Sanofi SA, Roche Holding AG, Novartis AG, Merck &
Co. Inc., Pfizer Inc., Johnson & Johnson, Takeda Pharmaceutical Company
Limited, Moderna, Inc., BioNTech SE, CSL Limited, and Sinovac Biotech Ltd.
These companies are actively involved in research and development activities,
collaborations, and strategic partnerships to expand their product portfolios
and gain a competitive edge in the market.
Comments
Post a Comment